Oral solid dosage form is the most important type of preparation and is becoming the focus in nowadays drug R&D, whether small-molecule targeted drugs or special oral preparations. In the past few years, the group has gradually established the technical system of the platform in cooperation with a third-party, and been in the process of developing a number of new drugs and generic drugs with unique clinical treatment value. Oral solid formulation technology will be one of the basic technology platforms for the long-term development of the group.

The progresses of the projects based on the oral solid formulation platform are summarized as follows:
        Obeticholic acid for the treatment of liver diseases has officially launched bioequivalence study and plans to apply for drug registration as soon as possible. The project is a generic version of a drug in the United States for the treatment of primary biliary cirrhosis (PBC) which has been launched in global market. As a country with a high prevalence rate of liver diseases, China has a huge market. The company commissioned a third-party company to break through the patent restrictions of the original drug, and has obtained the corresponding patent authorization in mainland China.
        Besides, the Group has initiated pre-clinical study of a JAK1 selective inhibitor, as JAK-STAT pathway has been recognized of great therapeutic value for autoimmune diseases. We expect to find a new drug (me-better) with therapeutic advantages and will initiate an IND submission as soon as possible.